Tivozanib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tivozanib
Accession Number
DB11800
Type
Small Molecule
Groups
Investigational
Description

Tivozanib has been used in trials studying the treatment and basic science of Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease, among others.

Structure
Thumb
Synonyms
  • Tivozanib
External IDs
AV 951 / AV-951 / AV951 / KIL-8951 / KRN 951 / KRN-951
Product Ingredients
IngredientUNIICASInChI Key
Tivozanib hydrochloride8A9H4VK35Z682745-41-1RQXMKRRBJITKRN-UHFFFAOYSA-N
Categories
UNII
172030934T
CAS number
475108-18-0
Weight
Average: 454.863
Monoisotopic: 454.104397445
Chemical Formula
C22H19ClN4O5
InChI Key
SPMVMDHWKHCIDT-UHFFFAOYSA-N
InChI
InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)
IUPAC Name
1-{2-chloro-4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-3-(5-methyl-1,2-oxazol-3-yl)urea
SMILES
COC1=C(OC)C=C2C(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=CC=NC2=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tivozanib.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tivozanib.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tivozanib.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Tivozanib.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
9911830
PubChem Substance
347828149
ChemSpider
8087481
BindingDB
50331095
ChEBI
91327
ChEMBL
CHEMBL1289494
ZINC
ZINC000001489430
PDBe Ligand
AV9
Wikipedia
Tivozanib
ATC Codes
L01XE34 — Tivozanib
PDB Entries
4ase

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAdvanced Solid Tumors1
1CompletedBasic ScienceHepatic Impairment1
1CompletedTreatmentAdvanced Solid Tumors / Locally Advanced or Metastatic Breast or Colorectal Cancer1
1CompletedTreatmentColorectal Cancers / Gastrointestinal Cancers1
1CompletedTreatmentFood Effect of Tivozanib in Health Subjects1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedTreatmentMetastatic Breast Cancer1
1CompletedTreatmentRenal Cell Adenocarcinoma1
1CompletedTreatmentTumors, Solid1
1, 2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
1, 2CompletedTreatmentAdvanced Adult Hepatocellular Carcinoma / Non-Resectable Hepatocellular Carcinoma1
1, 2CompletedTreatmentGastrointestinal Cancers1
1, 2RecruitingTreatmentHepatocellular,Carcinoma1
1, 2WithdrawnTreatmentEGFR Unknown or Wild-type / Lung Cancer Non-Small Cell Cancer (NSCLC) / Stage IV Disease1
2Active Not RecruitingTreatmentProstate Cancer1
2Active Not RecruitingTreatmentRecurrent Fallopian Tube Cancer / Recurrent Primary Peritoneal Cancer / Recurrent, Epithelial Ovarian Cancer1
2CompletedTreatmentColorectal Cancers1
2CompletedTreatmentGlioblastomas1
2CompletedTreatmentMetastatic Renal Cell Carcinoma1
2CompletedTreatmentRecurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1
2CompletedTreatmentRenal Cell Adenocarcinoma2
2TerminatedTreatmentFallopian Tube Cancer / Ovarian Cancer / Primary Peritoneal Carcinoma1
2TerminatedTreatmentHepatocellular Cancer1
2TerminatedTreatmentTriple Negative Breast Cancer (TNBC)1
2WithdrawnTreatmentRenal Cell Adenocarcinoma1
3Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
3CompletedTreatmentAdvanced Renal Cell Carcinoma2
Not AvailableCompletedTreatmentTumors, Solid1
Not AvailableWithdrawnTreatmentStage II Renal Cell Cancer / Stage III Renal Cell Cancer1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0521 mg/mLALOGPS
logP4.25ALOGPS
logP4.22ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)8.27ChemAxon
pKa (Strongest Basic)5.89ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area107.74 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity120.85 m3·mol-1ChemAxon
Polarizability44.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Ethers
Direct Parent
Diarylethers
Alternative Parents
Quinolines and derivatives / N-phenylureas / Anisoles / Phenoxy compounds / Alkyl aryl ethers / Chlorobenzenes / Pyridines and derivatives / Imidolactams / Aryl chlorides / Isoxazoles
show 10 more
Substituents
Diaryl ether / N-phenylurea / Quinoline / Phenoxy compound / Anisole / Phenol ether / Alkyl aryl ether / Halobenzene / Chlorobenzene / Aryl chloride
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 14:49 / Updated on March 01, 2020 23:46

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates